Bachem webinar on selecting the right peptide & oligonucleotide CDMO

Bubendorf, Switzerland: –Peptide technology specialist Bachem’s latest online webinar later this month will focus on finding the right development strategy and contract development and manufacturing partners for peptide and oligonucleotide based drugs.

The webinar ‘Trends in peptides and oligonucleotides – choosing a partner CDMO’ will look at the foreseeable future of peptides and oligonucleotides as versatile therapeutics with a growing range of applications and many similarities in terms of manufacturing and regulation.

Complex questions

Since innovative formulations often increase the complexity of the products and demand similarly innovative solutions, it becomes crucial for pharma drug developers to partner with a suitably experienced CDMO to support their product development and manufacturing needs and allow them to focus on their core role as researchers and innovators.

The webinar is free to register (see Resources) and will be hosted online on February 24, 2022, from 1730 hrs CEST (UTC+1).

Webinar hosts

The session will be moderated by Head of Bachem Group Communication, Dr. Daniel Grotzky, with key insights from Bachem Group Leader for Product Management, Dr. Tycho Leifels.

Dr. Leifels is an experienced life science portfolio professional with a 17 year track record of leading business development and pipeline strategy in various commercial roles in the life science industry including successful international product launches.

Dr. Grotzky is responsible for Bachem’s internal and external communications and investor relations, with a strong track record of communications in the life science industry, including more than a decade of experience in various communication leadership roles at the biopharmaceutical and diagnostics company Roche.

About Bachem

Bachem is a leading, innovation-driven company specializing in the development and manufacture of peptides and oligonucleotides. With over 50 years of experience and expertise, Bachem provides products for research, clinical development and commercial application to pharmaceutical and biotechnology companies worldwide and offers a comprehensive range of services.

Bachem operates internationally with headquarters in Switzerland and locations in Europe, the US and Asia. The company is listed on the SIX Swiss Exchange. For further information, see www.bachem.com.

Resources

Click on Bachem webinar on selecting the right peptide & oligonucleotide CDMO to register for the event.
Click on Bachems News to see latest News & Events.